TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
盛望徽Sheng, Wang-Huei
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
-
vicky90180@gmail.com
發表文獻
60筆
1
Chang HY, Tsai WC, Lee TF, Sheng WH. Mycobacterium gordonae infection in immunocompromised and immunocompetent hosts: A series of seven cases and literature review. J Formos Med Assoc. 2021 Jan;120(1 Pt 2):524-532. doi: 10.1016/j.jfma.2020.06.029. Epub 2020 Jul 4. PMID: 32631707.
2
Sheng WH, Liu WD, Wang JT, Chang SY, Chang SC. Dysosmia and dysgeusia in patients with COVID-19 in northern Taiwan. J Formos Med Assoc. 2021 Jan;120(1 Pt 2):311-317. doi: 10.1016/j.jfma.2020.10.003. Epub 2020 Oct 20. PMID: 33139151; PMCID: PMC7574720.
3
Hsieh MJ, Hsu NC, Lin YF, Shu CC, Chiang WC, Ma MH, Sheng WH. Developing and validating a model for predicting 7-day mortality of patients admitted from the emergency department: an initial alarm score by a prospective prediction model study. BMJ Open. 2021 Jan 4;11(1):e040837. doi: 10.1136/bmjopen-2020-040837. PMID: 33397665; PMCID: PMC7783526.
4
Yeong EK, Sheng WH. Does early bloodstream infection pose a significant risk of in-hospital mortality in adults with burns? J Microbiol Immunol Infect. 2021 Jan 23:S1684-1182(21)00018-9. doi: 10.1016/j.jmii.2021.01.004. Epub ahead of print. PMID: 33563562.
5
Huang K, Lin SW, Sheng WH, Wang CC. Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States. Sci Rep. 2021 May 26;11(1):11025. doi: 10.1038/s41598-021-90068-y. PMID: 34040014; PMCID: PMC8155195.
6
Chien YC, Lee YL, Liu PY, Lu MC, Shao PL, Lu PL, Cheng SH, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Lee WS, Shi ZY, Chen YS, Wang FD, Tseng SH, Chen YH, Sheng WH, Lee CM, Chen YH, Ko WC, Hsueh PR. National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017-2020. J Glob Antimicrob Resist. 2021 Sep;26:308-316. doi: 10.1016/j.jgar.2021.07.005. Epub 2021 Jul 18. PMID: 34289409; PMCID: PMC8437679.
7
Lee YL, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, Lu MC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Shao PL, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Tang HJ, Hsueh PR. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020. Int J Antimicrob Agents. 2021 Sep;58(3):106377. doi: 10.1016/j.ijantimicag.2021.106377. Epub 2021 Jun 21. PMID: 34166777.
8
Tsai HY, Lee YL, Liu PY, Lu MC, Shao PL, Lu PL, Cheng SH, Ko WC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Lee WS, Shi ZY, Chen YS, Wang FD, Tseng SH, Chen YH, Sheng WH, Lee CM, Chen YH, Liao CH, Hsueh PR. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). Int J Antimicrob Agents. 2021 Jul;58(1):106353. doi: 10.1016/j.ijantimicag.2021.106353. Epub 2021 May 5. PMID: 33961991.
9
Yuan CT, Wang JT, Sheng WH, Cheng PY, Kao CJ, Wang JY, Chen CY, Liau JY, Tsai JH, Lin YJ, Chen CC, Chen YC, Chang SC, Wu UI. Lymphadenopathy Associated With Neutralizing Anti-interferon-gamma Autoantibodies Could Have Monoclonal T-cell Proliferation Indistinguishable From Malignant Lymphoma and Treatable by Antibiotics: A Clinicopathologic Study. Am J Surg Pathol. 2021 Aug 1;45(8):1138-1150. doi: 10.1097/PAS.0000000000001731. PMID: 34010155.
10
Liu CH, Sun HY, Hsieh SM, Liu WC, Sheng WH, Liu CJ, Su TH, Tseng TC, Chen PJ, Hung CC, Kao JH. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. J Viral Hepat. 2021 Jun;28(6):887-896. doi: 10.1111/jvh.13502. Epub 2021 Apr 3. PMID: 33759290.
